Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: Refractory ascites (RA) is closely related to a high morbidity and mortality. In this study, we investigated predictors of RA development in patients with hepatitis B virus (HBV)-related cirrhosis who were hospitalized to control ascitic decompensation,and determined predictors for survival in patients who experienced RA. Materials and Methods: We analyzed 199 consecutive patients with HBV-related cirrhosis who were hospitalized to control ascitic decompensation between January 1996 and December 2008. Results: Multivariate analyses showed that only serum potassium at admission predicted RA development independently [p=0.013; hazard ratio (HR), 2.800; 95% confidence interval (CI), 1.166-6.722]. During the follow-up period, 16 (8.0%) patients experienced RA within 4.2 (range, 1.0-39.2) months after admission for controlling ascitic decompensation, and they survived a median of 8.7 (range, 3.9-51.3) months. Child-Pugh class and RA type were identified as independent prognostic factors affecting the survival in patients with RA (p=0.045; HR, 8.079; 95% CI, 1.231-67.984 and p=0.013; HR, 14.510; 95% CI, 1.771-118.874, respectively). Conclusion: Serum potassium was an independent predictor of RA development in patients with HBV-related cirrhosis who were hospitalized to control ascitic decompensation. After RA development, Child-Pugh class and RA type were independent predictors for survival.
Abstract
Purpose: Refractory ascites (RA) is closely related to a high morbidity and mortality. In this study, we investigated predictors of RA development in patients with hepatitis B virus (HBV)-related cirrhosis who were hospitalized to control ascitic decompensation,and determined predictors for survival in patients who experienced RA. Materials and Methods: We analyzed 199 consecutive patients with HBV-related cirrhosis who were hospitalized to control ascitic decompensation between January 1996 and December 2008. Results: Multivariate analyses showed that only serum potassium at admission predicted RA development independently [p=0.013; hazard ratio (HR), 2.800; 95% confidence interval (CI), 1.166-6.722]. During the follow-up period, 16 (8.0%) patients experienced RA within 4.2 (range, 1.0-39.2) months after admission for controlling ascitic decompensation, and they survived a median of 8.7 (range, 3.9-51.3) months. Child-Pugh class and RA type were identified as independent prognostic factors affecting the survival in patients with RA (p=0.045; HR, 8.079; 95% CI, 1.231-67.984 and p=0.013; HR, 14.510; 95% CI, 1.771-118.874, respectively). Conclusion: Serum potassium was an independent predictor of RA development in patients with HBV-related cirrhosis who were hospitalized to control ascitic decompensation. After RA development, Child-Pugh class and RA type were independent predictors for survival.
참고문헌 (29)
- Kim SU, "Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites", J Gastroenterol Hepatol, 23, pp.1722~1727 (2008)
- Lee JM, "Ascites and spontaneous bacterial peritonitis: an Asian perspective", J Gastroenterol Hepatol, 24, pp.1494~1503 (2009)
- Kim SU, "Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis", J Gastroenterol Hepatol, 25, pp.122~128 (2010)
- Ginés P, "Compensated cirrhosis: natural history and prognostic factors", Hepatology, 7, pp.122~128 (1987)
- Arroyo V, "Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club", Hepatology, 23, pp.164~176 (1996)
- Forns X, "Management of ascites and renal failure in cirrhosis", Semin Liver Dis, 14, pp.82~96 (1994)
- Martinet JP, "Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution", Dig Dis Sci, 42, pp.161~166 (1997)
- Ginès A, "Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis", Gastroenterology, 111, pp.1002~1010 (1996)
- Stanley MM, "Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites", N Engl J Med, 321, pp.1632~1638 (1989)
- Moreau R, "Clinical characteristics and outcome of patients with cirrhosis and refractory ascites", Liver Int, 24, pp.457~464 (2004)
- Ginès A, "Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites", Gastroenterology, 105, pp.229~236 (1993)
- Chutaputti A, "Management of refractory ascites and hepatorenal syndrome", J Gastroenterol Hepatol, 17, pp.456~461 (2002)
- O’Grady JG, "Acute liver failure: redefining the syndromes", Lancet, 342, pp.273~275 (1993)
- Adukauskiene D, "Acute liver failure in Lithuania", Medicina, 44, pp.536~540 (2008)
- Planas R, "Natural history of patients hospitalized for management of cirrhotic ascites", Clin Gastroenterol Hepatol, 4, pp.1385~1394 (2006)
- Salerno F, "Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients", Am J Gastroenterol, 88, pp.514~519 (1993)
- Cárdenas A, "Refractory ascites", Dig Dis, 23, pp.30~38 (2005)
- Rössle M, "A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites", N Engl J Med, 342, pp.1701~1707 (2000)
- Ginès P, "Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis", Gastroenterology, 123, pp.1839~1847 (2002)
- Quiroga J, "Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters", Hepatology, 21, pp.986~994 (1995)
- Moore KP, "The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club", Hepatology, 38, pp.258~266 (2003)
- Ginès P, "The management of ascites and hyponatremia in cirrhosis", Semin Liver Dis, 28, pp.43~58 (2008)
- Moini M, "Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation", Clin Transplant, 25, pp.638~645 (2011)
- Bernardi M, "Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content", Liver, 13, pp.156~162 (1993)
- Angeli P, "CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey", Hepatology, 44, pp.1535~1542 (2006)
- Biggins SW, "Evidence-based incorporation of serum sodium concentration into MELD", Gastroenterology, 130, pp.1652~1660 (2006)
- Heuman DM, "Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death", Hepatology, 40, pp.802~810 (2004)
- Fernández-Rodríguez CM, "Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response", Am J Gastroenterol, 105, pp.2164~2172 (2010)
- Kalaitzakis E, "Abstinence in patients with alcoholic liver cirrhosis: A follow-up study", Hepatol Res, 38, pp.869~876 (2008)